Israel Englander’s Teva Pharmaceuticals TEVA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$111M Buy
3,265,321
+1,371,476
+72% +$45.7M 0.04% 465
2026
Q1
$57M Buy
+1,893,845
New +$60.9M 0.02% 753
2025
Q4
Sell
-1,067,974
Closed -$26.3M 6458
2025
Q3
$21.6M Sell
1,067,974
-31,120
-3% -$547K 0.01% 1585
2025
Q2
$18.4M Sell
1,099,094
-4,396,395
-80% -$70.9M 0.01% 1655
2025
Q1
$84.5M Sell
5,495,489
-1,046,700
-16% -$18.7M 0.05% 441
2024
Q4
$144M Sell
6,542,189
-5,271,040
-45% -$95.9M 0.07% 253
2024
Q3
$213M Sell
11,813,229
-314,948
-3% -$5.51M 0.1% 158
2024
Q2
$197M Buy
12,128,177
+1,379,392
+13% +$21.2M 0.09% 191
2024
Q1
$152M Sell
10,748,785
-4,322,067
-29% -$54.5M 0.06% 279
2023
Q4
$157M Buy
15,070,852
+5,213,050
+53% +$48.7M 0.07% 254
2023
Q3
$101M Sell
9,857,802
-4,172,267
-30% -$38.8M 0.05% 370
2023
Q2
$106M Buy
14,030,069
+7,835,223
+126% +$63.5M 0.05% 343
2023
Q1
$54.8M Buy
6,194,846
+5,158,012
+497% +$51M 0.03% 637
2022
Q4
$9.46M Sell
1,036,834
-486,456
-32% -$4.24M 0.01% 2191
2022
Q3
$12.3M Sell
1,523,290
-8,563,015
-85% -$75.7M 0.01% 1889
2022
Q2
$75.8M Sell
10,086,305
-1,346,502
-12% -$11.7M 0.05% 422
2022
Q1
$107M Buy
11,432,807
+8,752,890
+327% +$73M 0.06% 313
2021
Q4
$21.5M Buy
2,679,917
+977,158
+57% +$8.82M 0.01% 1382
2021
Q3
$16.6M Buy
1,702,759
+1,534,493
+912% +$14.4M 0.01% 1500
2021
Q2
$1.67M Sell
168,266
-1,259,810
-88% -$13.3M ﹤0.01% 4174
2021
Q1
$16.5M Buy
1,428,076
+1,081,801
+312% +$12.4M 0.01% 1265
2020
Q4
$3.34M Sell
346,275
-730,775
-68% -$7M ﹤0.01% 2818
2020
Q3
$9.7K Buy
1,077,050
+960,583
+825% +$10.2M 0.01% 1280
2020
Q2
$1.44M Sell
116,467
-1,092,810
-90% -$12.4M ﹤0.01% 2763
2020
Q1
$10.9M Buy
1,209,277
+409,411
+51% +$4.19M 0.02% 804
2019
Q4
$7.84M Sell
799,866
-1,100,093
-58% -$9.82M 0.01% 1584
2019
Q3
$13.1M Buy
1,899,959
+1,888,057
+15,863% +$14.5M 0.02% 1085
2019
Q2
$110K Sell
11,902
-22,899
-66% -$276K ﹤0.01% 3876
2019
Q1
$546K Sell
34,801
-528,918
-94% -$9.33M ﹤0.01% 3214
2018
Q4
$8.69M Sell
563,719
-210,542
-27% -$4.32M 0.01% 1217
2018
Q3
$16.7M Sell
774,261
-4,851,590
-86% -$113M 0.02% 939
2018
Q2
$137M Buy
5,625,851
+5,549,041
+7,224% +$113M 0.18% 115
2018
Q1
$1.31M Sell
76,810
-2,889,126
-97% -$56.4M ﹤0.01% 2553
2017
Q4
$56.2M Buy
2,965,936
+1,071,583
+57% +$16.1M 0.08% 360
2017
Q3
$33.3M Buy
1,894,353
+1,888,189
+30,633% +$42.5M 0.05% 507
2017
Q2
$205K Sell
6,164
-1,468,824
-100% -$45.5M ﹤0.01% 3187
2017
Q1
$47.3M Buy
1,474,988
+1,367,636
+1,274% +$46.7M 0.09% 327
2016
Q4
$3.89M Sell
107,352
-1,646,808
-94% -$65.7M 0.01% 1496
2016
Q3
$80.7M Buy
1,754,160
+558,417
+47% +$29.1M 0.14% 137
2016
Q2
$60.1M Buy
1,195,743
+596,491
+100% +$31.8M 0.14% 158
2016
Q1
$32.1M Sell
599,252
-2,401,067
-80% -$141M 0.08% 298
2015
Q4
$197M Buy
3,000,319
+990,699
+49% +$61.2M 0.41% 26
2015
Q3
$113M Sell
2,009,620
-297,710
-13% -$19.3M 0.22% 80
2015
Q2
$136M Sell
2,307,330
-6,683,437
-74% -$412M 0.26% 62
2015
Q1
$560M Buy
8,990,767
+3,697,503
+70% +$215M 1.04% 2
2014
Q4
$304M Buy
5,293,264
+86,322
+2% +$4.81M 0.65% 3
2014
Q3
$280M Buy
5,206,942
+1,182,407
+29% +$62.6M 0.71% 4
2014
Q2
$211M Sell
4,024,535
-1,168,658
-23% -$59.7M 0.58% 9
2014
Q1
$274M Buy
5,193,193
+2,326,853
+81% +$108M 0.8% 3
2013
Q4
$115M Buy
2,866,340
+2,005,183
+233% +$79M 0.36% 23
2013
Q3
$32.5M Buy
861,157
+553,476
+180% +$21.6M 0.1% 185
2013
Q2
$12.1M Buy
+307,681
New +$12M 0.04% 533

Other funds holding TEVA

Israel Englander's TEVA Position: Q2 2026 in Review

Israel Englander increased its Teva Pharmaceuticals (TEVA) stake by 72% in Q2 2026, buying an estimated $45.7M and bringing the position to 3,265,321 shares worth $111M. The position accounts for 0.04% of the portfolio, ranked #465.

Israel Englander first reported a position in TEVA in Q2 2013 and has held it in 52 quarters since. The position peaked at $560M in Q1 2015. 671 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Israel Englander held 3,265,321 shares of Teva Pharmaceuticals worth $111M as of Q2 2026.
  • Israel Englander bought 1,371,476 Teva Pharmaceuticals shares in Q2 2026, an estimated $45.7M.
  • Teva Pharmaceuticals made up 0.04% of Israel Englander's portfolio in Q2 2026, its #465 holding.
  • Israel Englander first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Israel Englander's Teva Pharmaceuticals position peaked at $560M in Q1 2015.
  • 671 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.